I think TYME will get a decent pop with Monday's presentation (already had good run up) but it seems to me that the best results would come in early diagnosed patients, rather than those who have already failed 2 or 3 drug regimes and are more or less circling the drain. Serious side effects are very low. So basically I think this will be a sell on news situation, as I expect the SP to drift back down. What interests me more now in the cancer field is CYDY's ongoing basket trial of their leronlimab, which anecdotally has brought patient's CTC's down to zero, thereby effectively cutting off mets. JMO, as my real skill is in orthopedics, particularly joint replacement. Best wishes Mike.
Market Data 
Markets 
AI
